Cabozantinib is a dicarboxylic acid diamide, specifically N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide with the hydrogen at position 4 of the phenyl ring replaced by a (6,7-dimethoxyquinolin-4-yl)oxy group. It is a multi-tyrosine kinase inhibitor used as its malate salt in the treatment of progressive, metastatic medullary thyroid cancer. It functions as a tyrosine kinase inhibitor and antineoplastic agent, and is classified as a quinoline, organofluorine compound, aromatic ether, and dicarboxylic acid diamide.
